Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pizzolo

Showing results (171-180 of 210) with videos related to

Pageof 21
Sort By:
Clinical and Experimental Immunology|August 1, 1984
Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patientsG Semenzato, C Agostini, L Trentin, et al.
Journal of Clinical Immunology|November 1, 1988
Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritisG Semenzato, L M Bambara, D Biasi, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1990
Expression and gene rearrangement of the T-cell receptor in human thymomasA Scarpa, M Chilosi, P Capelli, et al.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Blood|December 15, 1994
Abnormal expression of the p53-binding protein MDM2 in Hodgkin's diseaseM Chilosi, C Doglioni, F Menestrina, et al.
Leukemia|November 1, 1991
Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytesR Zambello, M A Cassatella, L Trentin, et al.
The American Journal of Pathology|September 1, 1987
Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseasesM Chilosi, A Iannucci, F Menestrina, et al.
Leukemia|March 31, 1998
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicinG Todeschini, C Tecchio, V Meneghini, et al.
Cancer|December 15, 1987
The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditionsG Semenzato, F Pandolfi, T Chisesi, et al.
Lancet (London, England)|May 16, 1992
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxinB Falini, A Bolognesi, L Flenghi, et al.
Pageof 21

Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
Clinical and Experimental Immunology|August 1, 1984
Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patientsG Semenzato, C Agostini, L Trentin, et al.
Journal of Clinical Immunology|November 1, 1988
Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritisG Semenzato, L M Bambara, D Biasi, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1990
Expression and gene rearrangement of the T-cell receptor in human thymomasA Scarpa, M Chilosi, P Capelli, et al.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Blood|December 15, 1994
Abnormal expression of the p53-binding protein MDM2 in Hodgkin's diseaseM Chilosi, C Doglioni, F Menestrina, et al.
Leukemia|November 1, 1991
Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytesR Zambello, M A Cassatella, L Trentin, et al.
The American Journal of Pathology|September 1, 1987
Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseasesM Chilosi, A Iannucci, F Menestrina, et al.
Leukemia|March 31, 1998
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicinG Todeschini, C Tecchio, V Meneghini, et al.
Cancer|December 15, 1987
The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditionsG Semenzato, F Pandolfi, T Chisesi, et al.
Lancet (London, England)|May 16, 1992
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxinB Falini, A Bolognesi, L Flenghi, et al.
Pageof 21